• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

Introduction to 3-Amino-2,6-dichloro-4-(difluoromethyl)pyridine (CAS No. 1805322-91-1)

3-Amino-2,6-dichloro-4-(difluoromethyl)pyridine (CAS No. 1805322-91-1) is a versatile compound with significant applications in the fields of medicinal chemistry and pharmaceutical research. This pyridine derivative is characterized by its unique structural features, including an amino group, two chlorine atoms, and a difluoromethyl moiety, which collectively contribute to its diverse chemical and biological properties.

The synthesis of 3-Amino-2,6-dichloro-4-(difluoromethyl)pyridine has been extensively studied due to its potential as a building block in the development of novel drugs. The difluoromethyl group, in particular, has gained attention for its ability to enhance the metabolic stability and bioavailability of drug candidates. Recent research has highlighted the importance of fluorinated compounds in drug discovery, as they often exhibit improved pharmacokinetic profiles and reduced toxicity compared to their non-fluorinated counterparts.

In the context of medicinal chemistry, 3-Amino-2,6-dichloro-4-(difluoromethyl)pyridine has been explored as a scaffold for the design of inhibitors targeting various enzymes and receptors. For instance, studies have shown that derivatives of this compound can effectively inhibit kinases, which are key enzymes involved in cellular signaling pathways and are often implicated in diseases such as cancer and inflammatory disorders. The amino group provides a functional handle for further derivatization, allowing researchers to tailor the compound's properties to specific therapeutic needs.

The chlorine atoms in 3-Amino-2,6-dichloro-4-(difluoromethyl)pyridine also play a crucial role in its biological activity. Chlorinated pyridines have been shown to exhibit potent antiviral and antibacterial properties, making them valuable candidates for the development of new antimicrobial agents. Additionally, the presence of chlorine atoms can influence the compound's lipophilicity and solubility, which are important factors in drug delivery and absorption.

Recent advancements in synthetic methods have facilitated the efficient production of 3-Amino-2,6-dichloro-4-(difluoromethyl)pyridine. Techniques such as transition-metal-catalyzed cross-coupling reactions and electrophilic aromatic substitution have been employed to synthesize this compound with high yields and purity. These methods not only improve the scalability of production but also reduce the environmental impact associated with traditional synthetic routes.

In preclinical studies, 3-Amino-2,6-dichloro-4-(difluoromethyl)pyridine has demonstrated promising results in various disease models. For example, it has shown efficacy in inhibiting tumor growth in xenograft models of cancer and has exhibited anti-inflammatory effects in animal models of arthritis. These findings underscore the potential of this compound as a lead molecule for further drug development.

The safety profile of 3-Amino-2,6-dichloro-4-(difluoromethyl)pyridine is another important aspect that has been investigated. Toxicity studies have indicated that this compound is well-tolerated at therapeutic doses and does not exhibit significant adverse effects on major organs or systems. However, ongoing research is necessary to fully understand its long-term safety and potential side effects.

In conclusion, 3-Amino-2,6-dichloro-4-(difluoromethyl)pyridine (CAS No. 1805322-91-1) represents a promising compound with a wide range of applications in medicinal chemistry and pharmaceutical research. Its unique structural features make it an attractive candidate for the development of novel drugs targeting various diseases. As research continues to advance our understanding of this compound's properties and potential uses, it is likely to play an increasingly important role in the field of drug discovery.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)